COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

  1. Cong Zeng
  2. John P. Evans
  3. Karthik Chakravarthy
  4. Panke Qu
  5. Sarah Reisinger
  6. No-Joon Song
  7. Mark P. Rubinstein
  8. Peter G. Shields
  9. Zihai Li
  10. Shan-Lu Liu

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.ccell.2021.12.014
  2. ScreenIT

    SciScore for 10.1101/2021.12.28.21268398: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Ethicsnot detected.
    Sex as a biological variableSamples were collected between 31 and 121 days post-second mRNA vaccine dose (n = 23) for 8 breast cancer patients (all female) vaccinated with mRNA-1273 (n = 2) or BNT162b2 (n = 6) and for 15 lung cancer patients (6 female and 9 male) vaccinated with mRNA-1273 (n = 10) or BNT162b2 (n = 5).
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    HEK293T cells were transfected with pNL4-3-inGluc and various S constructs in a 2:1 ratio using polyethylenimine transfection.
    HEK293T
    suggested: None
    Following incubation, sera and virus was transferred to seeded HEK293T-ACE2 cells for infection.
    HEK293T-ACE2
    suggested: None
    Recombinant DNA
    SentencesResources
    Additionally, we utilized N-and C-terminally Flag-tagged SARS-CoV-2 S expression constructs that were generated and cloned into pcDNA3.1 using Kpn I and BamH I restriction enzyme cloning by GenScript Biotech (Piscataway, NJ).
    pcDNA3.1
    suggested: RRID:Addgene_79663)
    HEK293T cells were transfected with pNL4-3-inGluc and various S constructs in a 2:1 ratio using polyethylenimine transfection.
    pNL4-3-inGluc
    suggested: None
    Software and Algorithms
    SentencesResources
    50% neutralization titers (NT50) values were calculated from luminescence readout by least-squares-fit, non-linear regression performed in GraphPad Prism 5 (San Diego, CA).
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.12.28.21268398v1 on medRxiv